Cell surface-binding sites for progesterone mediate calcium uptake in human sperm.
Recent studies (e.g. Blackmore, P. F., Beebe, S. J., Danforth, D. R., and Alexander, N.) (1990) J. Biol. Chem. 265, 1376-1380) have shown that in human sperm, progesterone produces a rapid increase in intracellular free calcium ([Ca2+]i) and an induction of the acrosome reaction (e.g. Osman, R. A., Andria, M. L., Jones, A. D., and Meizel, S. (1989) Biochem, Biophys. Res. Commun. 160, 828-833). In this study, the location of progesterone receptors on the cell surface of human sperm was identified using progesterone immobilized on bovine serum albumin (BSA) (progesterone 3-(O-carboxymethyl)oxime:BSA) as well as progesterone and its 3-O-carboxymethyloxime derivative. Using fluorescence microscopy, BSA-fluorescein isothiocyanate was shown to be excluded from intact sperm, thus validating the use of progesterone 3-(O-carboxymethyl)oxime:BSA to identify cell surface-binding sites for progesterone. The immobilized progesterone and the 3-O-carboxymethyloxime derivative rapidly increased [Ca2+]i and were full agonists, although they were approximately 1.5 orders of magnitude less potent than progesterone. They also displayed an identical time course to increase [Ca2+]i as free progesterone, and the entire increase in [Ca2+]i was due to the influx of Ca2+. This progesterone-mediated response displayed different steroid receptor characteristics since the very potent inhibitors of genomic progesterone responses, RU38486 and ZK98.299, were very ineffective at inhibiting the progesterone-mediated increase in [Ca2+]i. Also the synthetic progestins megestrol, medroxyprogesterone acetate, norgestrel, norethynodrel, norethindrone, R5020, and cyproterone acetate did not mimic the effects of progesterone to increase [Ca2+]i. It is proposed that a distinct nongenomic cell surface receptor for progesterone exists in human sperm.
Blackmore
P F
PF
Department of Pharmacology, Eastern Virginia Medical School, Norfolk 23501.
Neulen
J
J
Lattanzio
F
F
Beebe
S J
SJ
D002118:Calcium / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism / Q000648:ultrastructure; D002606:Charcoal / Q000494:pharmacology; D003534:Cyproterone / Q000031:analogs & derivatives / Q000494:pharmacology; D017373:Cyproterone Acetate; D004533:Egtazic Acid; D006067:Gonanes / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D007811:Lanthanum / Q000494:pharmacology; D008297:Male; D008856:Microscopy, Fluorescence; D009640:Norethindrone / Q000494:pharmacology; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012710:Serum Albumin, Bovine; D013094:Spermatozoa / Q000378:metabolism* / Q000648:ultrastructure
D006067:Gonanes; D011980:Receptors, Progesterone; D002606:Charcoal; D012710:Serum Albumin, Bovine; D011374:Progesterone; D017373:Cyproterone Acetate; D004533:Egtazic Acid; D007811:Lanthanum; D003534:Cyproterone; C053238:onapristone; D002118:Calcium; D009640:Norethindrone